Socioeconomic Status and the Incidence of ESRD

American Journal of Kidney Diseases

Volumn 51, Issue 4, 2008, Pages 563-572

  Ward, Michael M ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

autosomal dominant polycystic kidney disease; diabetes mellitus; end stage renal disease; health disparities; Socioeconomic status; systemic lupus erythematosus

Indexed keywords

ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SOCIOECONOMICS; UNITED STATES;

ADULT; DIABETES COMPLICATIONS; FEMALE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MALE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RETROSPECTIVE STUDIES; RISK FACTORS; SOCIOECONOMIC FACTORS;

EID: 40849085653     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.11.023     Document Type: Article

References (55)

1. Levey A.S., Coresh J., Balk E., et al. National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
2. Coresh J., Astor B.C., Greene T., Eknoyan G., and Levey A.S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41 (2003) 1-12
3. Whittle J.C., Whelton P.K., Seidler A.J., and Klag M.J. Does racial variation in risk factors explain black-white differences in the incidence of hypertensive end-stage renal disease?. Arch Intern Med 151 (1991) 1359-1364
4. Brancati F.L., Whittle J.C., Whelton P.K., Seidler A.J., and Klag M.J. The excess incidence of diabetic end-stage renal disease among blacks. A population-based study of potential explanatory factors. JAMA 268 (1992) 3079-3084
5. Cass A., Cunningham J., Wang Z., and Hoy W. Social disadvantage and variation in the incidence of end-stage renal disease in Australia capital cities. Aust N Z J Public Health 25 (2001) 322-326
6. Maheswaran R., Payne N., Meechan D., et al. Socioeconomic deprivation, travel distance, and renal replacement therapy in the Trent Region, United Kingdom 2000: An ecological study. J Epidemiol Community Health 57 (2003) 523-524
7. Li S., McAlpine D.D., Liu J., Li S., and Collins A.J. Differences between blacks and whites in the incidence of end-stage renal disease and associated risk factors. Adv Ren Replace Ther 11 (2004) 5-13
8. Young E.W., Mauger E.A., Jiang K.-H., Port F.K., and Wolfe R.A. Socioeconomic status and end-stage renal disease in the United States. Kidney Int 45 (1994) 907-911
9. Byrne C., Nedelman J., and Luke R.G. Race, socioeconomic status, and the development of end-stage renal disease. Am J Kidney Dis 23 (1994) 16-22
10. Perneger T.V., Whelton P.K., and Klag M.J. Race and end-stage renal disease. Socioeconomic status and access to health care as mediating factors. Arch Intern Med 155 (1995) 1201-1208
11. Klag M.J., Whelton P.K., Randall B.L., Meaton J.D., Brancati F.L., and Stamler J. End-stage renal disease in African-American and white men. 16-Year MRFIT findings. JAMA 277 (1997) 1293-1298
12. Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47 (1995) 1703-1720
13. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342 (2000) 381-389
14. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA 290 (2003) 2159-2167
15. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
16. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 28 (1995) 103-117
17. Hellman R., Regan J., and Rosen H. Effect of intensive treatment of diabetes of the risk of death or renal failure in NIDDM and IDDM. Diabetes Care 20 (1997) 258-264
18. Levin S.R., Coburn J.W., Abraira C., et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Diabetes Care 23 (2000) 1478-1485
19. Austin III H.A., Klippel J.H., Balow J.E., et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314 (1986) 614-619
20. Illei G.G., Austin H.A., Crane M., et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 135 (2001) 248-257
21. Contreras G., Pardo V., Leclercq B., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 350 (2004) 971-980
22. Johnson A.M., and Gabow P.A. Identification of patients with autosomal dominant polycystic kidney disease at high risk for end-stage renal disease. J Am Soc Nephrol 8 (1997) 1560-1567
23. Schrier R.W., McFann K.K., and Johnson A.M. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int 63 (2003) 678-685
24. Paterson A.D., Magistroni R., He N., et al. Progressive loss of renal function is an age-dependent heritable trait in type 1 autosomal dominant polycystic kidney disease. J Am Soc Nephrol 16 (2005) 755-762
25. US Renal Data System. USRDS 2005 Annual Data Report (2005), The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD
26. Yost K., Perkins C., Cohen R., Morris C., and Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12 (2001) 703-711
27. Diez Roux A.V., Kiefe C.I., Jacobs Jr. D.R., et al. Area characteristics and individual-level socioeconomic position indicators in three population-based epidemiologic studies. Ann Epidemiol 11 (2001) 395-405
28. Census 2000 Summary File 3-United States/prepared by the US Census Bureau (2002). http://factfinder.census.gov Accessed December 22, 2005
29. Merkin S.S., Coresh J., Diez Roux A.V., Taylor H.A., and Powe N.R. Area socioeconomic status and progressive CKD: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 46 (2005) 203-213
30. Shoham D.A., Vupputuri S., Diez Roux A.V., et al. Kidney disease in life-course socioeconomic context: The Atherosclerotic Risk in Communities (ARIC) Study. Am J Kidney Dis 49 (2007) 217-226
31. Beach M.C., Hill-Briggs F., and Cooper L.A. Racial and ethnic differences in receipt and use of health information in encounters between patients and physicians. Med Care 44 (2006) 97-99
32. Lloyd C.E., Wing R.R., Orchard T.J., and Becker D.J. Psychosocial correlates of glycemic control: The Pittsburgh Epidemiology of Diabetes Complications (EDC) Study. Diabetes Res Clin Pract 21 (1993) 187-195
33. Bihan H., Laurent S., Sass C., et al. Association among individual deprivation, glycemic control, and diabetes complications: The EPICES score. Diabetes Care 28 (2005) 2680-2685
34. Kuo Y.-F., Ray L.A., Raji M.A., Espino D.V., Markides K.S., and Goodwin J.S. Inconsistent use of diabetes medications, diabetes complications, and mortality in older Mexican Americans over a 7-year period. Diabetes Care 26 (2003) 3054-3060
35. Bell R.A., Camacho F., Goonan K., et al. Quality of diabetes care among low-income patients in North Carolina. Am J Prev Med 21 (2001) 124-131
36. Chaturvedi N., Stephenson J.M., and Fuller J.H. The relationship between socioeconomic status and diabetes control and complications in the EURODIAB IDDM Complications study. Diabetes Care 19 (1996) 423-430
37. Karter A.J., Ferrara A., Liu J.Y., Moffet H.H., Ackerson L.M., and Selby J.V. Ethnic disparities in diabetic complications in an insured population. JAMA 287 (2002) 2519-2527
38. Goldman D.P., and Smith J.P. Can patient self-management help explain the SES health gradient?. Proc Natl Acad Sci U S A 99 (2002) 10929-10934
39. Ward M.M. Medical insurance, socioeconomic status, and age at onset of endstage renal disease in patients with lupus nephritis. J Rheumatol 34 (2007) 2024-2027
40. Vermeire E., Wens J., van Royen P., Biot Y., Hearnshaw H., and Lindenmeyer A. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev CD003638 (2005)
41. Bruce I.N., Gladman D.D., and Urowitz M.B. Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. Arthritis Care Res 13 (2000) 406-408
42. Garcia Popa-Lisseanu M.G., Greisinger A., Richardson M., et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol 32 (2005) 913-919
43. Thom D.H., Ribisl K.M., Stewart A.L., and Luke D.A. Further validation and reliability testing of the Trust in Physician Scale. The Stanford Trust Study Physicians. Med Care 37 (1999) 510-517
44. Schillinger D., Grumbach K., Piette J., et al. Association of health literacy with diabetes outcomes. JAMA 288 (2002) 475-482
45. Singh-Manoux A., and Marmot M. Role of socialization in explaining social inequalities in health. Soc Sci Med 60 (2005) 2129-2133
46. Helman C.G. Culture, Health and Illness (2001), Arnold, New York, NY
47. Whitfield K.E., Weidner G., Clark R., and Anderson N.B. Sociodemographic diversity and behavioral medicine. J Consult Clin Psychol 70 (2002) 463-481
48. Dunlop D.D., Manheim L.M., Song J., and Chang R.W. Gender and ethnic/racial disparities in health care utilization among older adults. J Gerontol B Psychol Sci Soc Sci 57 suppl (2002) S221-S233
49. Chakravarty E.F., Bush T.M., Manzi S., Clarke A.E., and Ward M.M. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: Estimates using hospitalization data. Arthritis Rheum 56 (2007) 2092-2093
50. Geronimus A.T., and Bound J. Use of census-based aggregate variables to proxy for socioeconomic group: Evidence from national samples. Am J Epidemiol 148 (1998) 475-486
51. Kreiger N., Chen J.T., Waterman P.D., Soobader M.-J., Subramanian S.V., and Carson R. Choosing area based socioeconomic measures to monitor social inequalities in low birth weight and childhood lead poisoning: The Public Health Disparities Geocoding Project (US). J Epidemiol Community Health 57 (2003) 186-199
52. Smith G.D., Neaton J.D., Wentworth D., Stamler R., and Stamler J. Socioeconomic differentials in mortality risk among men screened for the Multiple Risk Factor Intervention Trial: I. White men. Am J Public Health 86 (1996) 486-496
53. Smith G.D., Neaton J.D., Wentworth D., Stamler R., and Stamler J. Socioeconomic differentials in mortality risk among men screened for the Multiple Risk Factor Intervention Trial: II. Black men. Am J Public Health 86 (1996) 497-504
54. Banks J., Marmot M., Oldfield Z., and Smith J.P. Disease and disadvantage in the United States and in England. JAMA 295 (2006) 2037-2045
55. Phelan J.C., and Link B.G. Controlling disease and creating disparities: A fundamental cause perspective. J Gerontol B Psychol Sci Soc Sci 60B (2005) 27-33